ORCA
Online Research @ CardiffÂ
Browse by Current Cardiff authors
![[up]](/style/images/multi_up.png)
Up a levelNumber of items: 3.
Kotecha, Sarah Joanne, Lowe, John  ORCID: https://orcid.org/0000-0003-4772-1879, Gillespie, David ORCID: https://orcid.org/0000-0002-6934-2928, Perez-Alijas, Mahuampi, Aboklaish, Ali F, Mahachi, Tarirai Lincoln, Cumming, Oliver Sebastian, Harris, Debbie ORCID: https://orcid.org/0000-0002-7073-7724, Hubbard, Marie, Thomas-Jones, Emma, Jones, Tim, Ladell, Kirsten, Moore, Catherine, Humpreys, Ian, Grigg, Jonathan, Berrington, Janet and Kotecha, Sailesh ORCID: https://orcid.org/0000-0003-3535-7627
2026.
Randomised, double-blind, parallel group, placebo-controlled, trial of Bactek for the prevention of lower respiratory tract infections in preterm infants in the UK: BALLOON study - study protocol.
BMJ Open
16
(3)
, e107929.
10.1136/bmjopen-2025-107929
|
|
|
|
Russell, Nigel H., Othman, Jad, Cumming, Oliver Sebastian, Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Tedjaseputra, Aditya, Potter, Nicola, Jovanovic, Jelena, Gilkes, Amanda Frances, Batten, Leona, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Hinson, Emily L., Runglall, Manohursingh, Aucken, Phoebe, Kottaridis, Panagiotis, Cavenagh, James Durrell, Arnold, Claire, Freeman, Sylvie D., Dennis, Mike, Knapper, Steven and Dillon, Richard James
2025.
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 mutated AML.
Blood Advances
9
(24)
, pp. 6455-6466.
10.1182/bloodadvances.2025017244
|
|
|
Russell, Nigel, Cumming, Oliver, Othman, Jad, Dillon, Richard, Potter, Nicola, Wilhelm-Benartzi, Charlotte ORCID: https://orcid.org/0000-0003-4927-6158, Jovanovic, Jelena, Gilkes, Amanda, Batten, Leona, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Laura Hinson, Emily, Kottaridis, Panagiotis, Cavenagh, Jamie, Arnold, Claire, Dennis, Mike and Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441
2023.
P484: Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Updated toxicity and interim survival analysis from the NCRI AML19v2 "Midotarg" Pilot Trial.
HemaSphere
7
(S3)
, e13145db.
10.1097/01.HS9.0000968844.13145.db
|
|
|